In the News

This article may contain information for uses of our product that are not approved in certain countries or regions.

In the United States, RECELL® is approved for use in patients suffering acute thermal burns. Use of RECELL in other patient populations is either prohibited by United States law or may be made available pursuant to a relevant investigational device exemption granted by the FDA (and likewise limited by United States law to investigational use only) or otherwise prohibited.


In the news video thumbnail

AVITA Medical is a regenerative medicine company focused on the development and commercialization of innovative therapies with the power to transform lives. Harnessing the regenerative properties of a patient’s own skin, AVITA Medical’s RECELL® System was approved by the U.S. Food and Drug Administration (FDA) in September 2018.

 


RECELL® System


Avita Medical Recell Product

The RECELL® System is the first new PMA-approved treatment in more than 20 years for acute thermal burn wounds.

Clinical Outcomes


Avita Medical Clinical Outcome

We’re elevating the standard of care for the treatment of skin restoration.

Pipeline


We’re exploring the potential of this novel technology platform to harness the regenerative properties of a patient’s own skin across a number of dermatological indications.

At AVITA Medical, patients are at the center of what we do. They guide and inspire our tireless dedication to advance bold innovation in regenerative medicine to deliver medical outcomes that transform lives.


The RECELL® System

This website stores cookies on your computer. These cookies are used to improve your website experience and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our privacy policy.